REG - IQ-AI Limited - IB awarded a $100,000 grant

IQ-AIAnnouncement

02/02/2024 08:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240202:nRSB8587Ba&default-theme=true

RNS Number : 8587B  IQ-AI Limited  02 February 2024

IQ-AI Ltd

("IQ-AI" or the "Company")

 

IB awarded a $100,000 grant by the Musella Foundation

Imaging Biometrics, LLC (IB), a wholly owned subsidiary of IQ-AI Ltd (LSE:
IQAI), announces that it has been awarded a $100,000 grant by the Musella
Foundation For Brain Tumor Research & Information, Inc. The grant will
help support the launch of the recently announced intermediate group expanded
access program (iEAP). The iEAP will allow brain tumor patients access to oral
(pill form) gallium maltolate (GaM) outside of the on-going phase 1 clinical
trial on-going at the Medical College of Wisconsin (MCW).

 

The Musella Foundation provided an initial award towards the on-going phase 1
clinical trial being conducted at the Medical College of Wisconsin (MCW).
Since then, IB has maintained and fostered a close relationship with The
Musella Foundation.

 

"Our interest in this particular agent is growing. It appears to be extremely
well tolerated and may possess clinical benefit for patients who have
exhausted standard therapies," said Dr. Al Musella, Founder and President of
The Musella Foundation.

 

The grant will be used to facilitate the iEAP including writing and submitting
the study protocol, patient screening and on-boarding, and more.

 

"This iEAP will enable brain tumor patients with limited or no other treatment
alternatives to gain access to oral GaM. We appreciate the support from the
Musella Foundation and IQ-AI who helped make this happen," said Dr. Jennifer
Connelly, MD, Professor of Neurology at MCW and co-PI of the trial.

 

 

--ENDS-

 

The Directors of the Company accept responsibility for the contents of this
announcement.

 

For further information, please contact:

 

 IQ-AI Ltd

 Trevor Brown/Vinod Kaushal/Brett Skelly/Michael Schmainda

 Tel: 020 7469 0930 (tel:020%207469%200930)
 Peterhouse Capital Limited (Financial Adviser and Broker)

 Lucy Williams/Heena Karani

 Tel: 020 7220 9797 (tel:020%207220%209797)

 

 

About The Musella Foundation
The Musella Foundation For Brain Tumor Research & Information, Inc is a
501(C)3 nonprofit public charity dedicated to helping brain tumor patients
through emotional and financial support, education, advocacy and raising money
for brain tumor research. Visit virtualtrials.org for more information.

 

About Imaging Biometrics® LLC:  IB is a wholly owned subsidiary of IQ-AI
Limited, (LON: IQAI), and focuses on delivering quantitative imaging platforms
and therapeutics that transform how clinicians diagnose and treat patients
more efficiently and effectively. For more information about Imaging
Biometrics, visit the company's website at www.imagingbiometrics.com
(https://eur01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fprotect-eu.mimecast.com%2Fs%2FM_SLCE9EkfljEqsNN5Gd%3Fdomain%3Dimagingbiometrics.com&data=05%7C02%7Chk%40peterhousecap.com%7Cfeccf97d46e64dc9345e08dc150933d2%7C84c2ab3d172a440aaca526a12faeab25%7C0%7C0%7C638408376478871141%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=AWlx9geNOFrkZzGTLgpNtuXp1951MeR4%2BdkwkjzAgjc%3D&reserved=0)
. Follow IB on Twitter, @IQAI_IB.

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  STRTTMPTMTJMMFI